References
- Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12:s3-9
- Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis 2002;8:244-50
- Feagan BG, Lémann M, Befrits R, et al. Recommendations for the treatment of Crohn’s disease with tumor necrosis factor antagonists: an expert consensus report. Inflamm Bowel Dis 2012;18:152-60
- Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004;99:91-6
- Burger D, Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology 2011;140:1827-37.e2
- Kane S, Dixon L. Adherence rates with infliximab therapy in Crohn’s disease. Aliment Pharmacol Ther 2006;24:1099-103
- Carter CT, Waters HC, Smith DB. Effect of a continuous measure of adherence with infliximab maintenance treatment on inpatient outcomes in Crohn’s disease. Patient Prefer Adherence 2012;6:417-26
- Kane SV, Chao J, Mulani PM. Adherence to Infliximab Maintenance Therapy and Health Care Utilization and costs by Crohn’s Disease Patients. Adv Ther 2009;26:936-46
- Carter CT, Waters HC, Smith DB. Impact of infliximab adherence on Crohn’s disease-related healthcare utilization and inpatient costs. Adv Ther 2011;28:671-83
- Selinger CP, Robinson A, Leong RW. Clinical impact and drivers of non-adherence to maintenance medication for inflammatory bowel disease. Expert Opin Drug Saf 2011;10:863-70
- Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7
- Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362:1383-95
- Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003;348:601-8
- Fefferman DS, Farrell RJ. Immunogenicity of biological agents in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:497-503
- Trindale AJ, Ehrlich A, Kornbluth A, et al. Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflamm Bowel Dis 2011;17:599-604
- US Department of Labor, Bureau of Labor Statistics. All Urban Consumers, medical services component, Consumer Price Index. Washington D.C., USA http://www.bls.gov. Accessed May 20, 2014
- Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med 2004;23:2937-60
- Wan GJ, Kozma CM, Slaton TL, et al. Inflammatory bowel disease: Healthcare costs for patients who are adherent or non-adherent with infliximab therapy. J Med Economics 2014;17:384-93